BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 26063023)

  • 21. Section 3. Current status of downstaging of hepatocellular carcinoma before liver transplantation.
    Sharr WW; Chan SC; Lo CM
    Transplantation; 2014 Apr; 97 Suppl 8():S10-7. PubMed ID: 24849822
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver transplantation versus liver resection for hepatocellular carcinoma: a meta-analysis.
    Xu XS; Liu C; Qu K; Song YZ; Zhang P; Zhang YL
    Hepatobiliary Pancreat Dis Int; 2014 Jun; 13(3):234-41. PubMed ID: 24919605
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term results with multimodal adjuvant therapy and liver transplantation for the treatment of hepatocellular carcinomas larger than 5 centimeters.
    Roayaie S; Frischer JS; Emre SH; Fishbein TM; Sheiner PA; Sung M; Miller CM; Schwartz ME
    Ann Surg; 2002 Apr; 235(4):533-9. PubMed ID: 11923610
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Liver transplantation for hepatocellular carcinoma recurrence after liver resection: why deny this chance of cure?
    De Carlis L; Di Sandro S; Giacomoni A; Mangoni I; Lauterio A; Mihaylov P; Cusumano C; Rampoldi A
    J Clin Gastroenterol; 2013 Apr; 47(4):352-8. PubMed ID: 23188072
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prognostic role of plasma vascular endothelial growth factor in patients with hepatocellular carcinoma undergoing liver transplantation.
    Zhang W; Kim R; Quintini C; Hashimoto K; Fujiki M; Diago T; Eghtesad B; Miller C; Fung J; Tan A; Menon KV; Aucejo F
    Liver Transpl; 2015 Jan; 21(1):101-11. PubMed ID: 25283528
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma.
    Antwi SO; Habboush YY; Chase LA; Lee DD; Patel T
    Ann Hepatol; 2018 Oct; 17(6):969-979. PubMed ID: 30600299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Combined Hangzhou criteria with neutrophil-lymphocyte ratio is superior to other criteria in selecting liver transplantation candidates with HBV-related hepatocellular carcinoma.
    Xiao GQ; Yang JY; Yan LN
    Hepatobiliary Pancreat Dis Int; 2015 Dec; 14(6):588-95. PubMed ID: 26663006
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Transarterial chemoembolization versus hepatic resection in hepatocellular carcinoma treatment: a meta-analysis.
    Tian X; Dai Y; Wang DQ; Zhang L; Sui CG; Meng FD; Jiang SY; Liu YP; Jiang YH
    Drug Des Devel Ther; 2015; 9():4431-40. PubMed ID: 26309396
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Pretransplant absolute monocyte count in peripheral blood predicts posttransplant tumor prognosis in patients undergoing liver transplantation for hepatocellular carcinoma.
    Kim YK; Kim SH; Lee SD; Lee SA; Park SJ
    Hepatobiliary Pancreat Dis Int; 2014 Jun; 13(3):250-8. PubMed ID: 24919607
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Time of hepatocellular carcinoma recurrence after liver resection and alpha-fetoprotein are important prognostic factors for salvage liver transplantation.
    Lee S; Hyuck David Kwon C; Man Kim J; Joh JW; Woon Paik S; Kim BW; Wang HJ; Lee KW; Suh KS; Lee SK
    Liver Transpl; 2014 Sep; 20(9):1057-63. PubMed ID: 24862741
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Impact of Pretransplant Bridging Locoregional Therapy for Patients With Hepatocellular Carcinoma Within Milan Criteria Undergoing Liver Transplantation: Analysis of 3601 Patients From the US Multicenter HCC Transplant Consortium.
    Agopian VG; Harlander-Locke MP; Ruiz RM; Klintmalm GB; Senguttuvan S; Florman SS; Haydel B; Hoteit M; Levine MH; Lee DD; Taner CB; Verna EC; Halazun KJ; Abdelmessih R; Tevar AD; Humar A; Aucejo F; Chapman WC; Vachharajani N; Nguyen MH; Melcher ML; Nydam TL; Mobley C; Ghobrial RM; Amundsen B; Markmann JF; Langnas AN; Carney CA; Berumen J; Hemming AW; Sudan DL; Hong JC; Kim J; Zimmerman MA; Rana A; Kueht ML; Jones CM; Fishbein TM; Busuttil RW
    Ann Surg; 2017 Sep; 266(3):525-535. PubMed ID: 28654545
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Benefit of Treating Hepatocellular Carcinoma Recurrence after Liver Transplantation and Analysis of Prognostic Factors for Survival in a Large Euro-American Series.
    Sapisochin G; Goldaracena N; Astete S; Laurence JM; Davidson D; Rafael E; Castells L; Sandroussi C; Bilbao I; Dopazo C; Grant DR; Lázaro JL; Caralt M; Ghanekar A; McGilvray ID; Lilly L; Cattral MS; Selzner M; Charco R; Greig PD
    Ann Surg Oncol; 2015 Jul; 22(7):2286-94. PubMed ID: 25472651
    [TBL] [Abstract][Full Text] [Related]  

  • 33. AFP level and histologic differentiation predict the survival of patients with liver transplantation for hepatocellular carcinoma.
    Yaprak O; Akyildiz M; Dayangac M; Demirbas BT; Guler N; Dogusoy GB; Yuzer Y; Tokat Y
    Hepatobiliary Pancreat Dis Int; 2012 Jun; 11(3):256-61. PubMed ID: 22672818
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Recurrence After Liver Transplantation for Hepatocellular Carcinoma: A New MORAL to the Story.
    Halazun KJ; Najjar M; Abdelmessih RM; Samstein B; Griesemer AD; Guarrera JV; Kato T; Verna EC; Emond JC; Brown RS
    Ann Surg; 2017 Mar; 265(3):557-564. PubMed ID: 27611615
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Predictive value of nodule size and differentiation in HCC recurrence after liver transplantation.
    Guerrini GP; Pinelli D; Di Benedetto F; Marini E; Corno V; Guizzetti M; Aluffi A; Zambelli M; Fagiuoli S; Lucà MG; Lucianetti A; Colledan M
    Surg Oncol; 2016 Dec; 25(4):419-428. PubMed ID: 26403621
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Downstaging of hepatocellular cancer before liver transplant: long-term outcome compared to tumors within Milan criteria.
    Yao FY; Mehta N; Flemming J; Dodge J; Hameed B; Fix O; Hirose R; Fidelman N; Kerlan RK; Roberts JP
    Hepatology; 2015 Jun; 61(6):1968-77. PubMed ID: 25689978
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Patient Selection by Tumor Markers in Liver Transplantation for Advanced Hepatocellular Carcinoma.
    Lee HW; Song GW; Lee SG; Kim JM; Joh JW; Han DH; Kim SI; Kim SH; Kim DS; Cho JY; Suh KS
    Liver Transpl; 2018 Sep; 24(9):1243-1251. PubMed ID: 29575509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Outcome of liver transplantation for hepatocellular carcinoma -- a single center experience.
    Iacob R; Iacob S; Gheorghe L; Gheorghe C; Hrehoreţ D; Brașoveanu V; Croitoru A; Herlea V; Popescu I
    Chirurgia (Bucur); 2013; 108(4):446-50. PubMed ID: 23958083
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Wait Time of Less Than 6 and Greater Than 18 Months Predicts Hepatocellular Carcinoma Recurrence After Liver Transplantation: Proposing a Wait Time "Sweet Spot".
    Mehta N; Heimbach J; Lee D; Dodge JL; Harnois D; Burns J; Sanchez W; Roberts JP; Yao FY
    Transplantation; 2017 Sep; 101(9):2071-2078. PubMed ID: 28353492
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Impact of treatment modalities on patients with recurrent hepatocellular carcinoma after liver transplantation: Preliminary experience.
    Yang Z; Wang S; Tian XY; Xie QF; Zhuang L; Li QY; Chen CZ; Zheng SS
    Hepatobiliary Pancreat Dis Int; 2020 Aug; 19(4):365-370. PubMed ID: 32553774
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.